Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes.

Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Donald M. Miller(University of Louisville), David T. Curiel(Washington University in St. Louis), Charles A. Mayfield(Baylor College of Medicine), C. Ryan Miller(University of North Carolina at Chapel Hill), R. A. Chee-Awai(University of Alabama)
PubMed
April 1, 1996
Cited by 20

Related Papers

Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k